The coronavirus disease 2019 (COVID-19) outbreak emerged in December 2019 in China
and rapidly spread worldwide. Inflammatory bowel disease (IBD) patients are likely
to be more susceptible to viral infections, and this is significantly influenced by
the type of therapy they receive. Thus, issues specifically concerning the medical
treatment of IBD patients were shortly addressed at the beginning of the pandemic.
However, recently available data on the occurrence and outcome of SARS-CoV-2 infection
in IBD patients does not address the concerns raised at the beginning of the pandemic.
Growing evidence and the rapid changes happening over the past few weeks have helped
elucidate the current situation, contribute to our understanding of the disease, and
many previously raised questions could now be answered. We hereby summarise available
evidence regarding viral infections and IBD, focusing on SARS-CoV infections, and
we provide practical recommendations related to patient management during the COVID-19